Keros Therapeutics, Inc.

NASDAQ:KROS

61.09 (USD) • At close October 17, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 0.0370.0830.1430.00800000.102000.1002.52.52.52.52.52.52.5
Cost of Revenue 0.3060.2770.2470.5510.5450.6890.4480.3370.5140.3160.3020.2239.9830.1799.6748.3957.2648.5274.133.8544.4974.867
Gross Profit -0.269-0.194-0.104-0.543-0.545-0.689-0.448-0.337-0.414-0.31619.698-0.223-9.883-0.179-9.674-5.895-4.764-6.027-1.63-1.354-1.997-2.367
Gross Profit Ratio -7.27-2.337-0.727-67.8750000-4.1400.9850-98.8300-2.358-1.906-2.411-0.652-0.542-0.799-0.947
Reseach & Development Expenses 40.51538.25837.49334.1432.53431.09124.86721.03923.28118.07818.83414.8329.98311.4959.6748.3957.2648.5274.1613.8544.4974.867
General & Administrative Expenses 9.96110.3089.1059.1488.8037.7787.0936.9377.4476.0486.0335.3655.6584.2743.6173.5533.651.9771.0670.9720.6540.491
Selling & Marketing Expenses -0.306000000000000000000000
SG&A 9.65510.3089.1059.1488.8037.7787.0936.9377.4476.0486.0335.3655.6584.2743.6173.5533.651.9771.0670.9720.6540.491
Other Expenses -0.196-0.437-10.9433.843.8323.0652.242-3.705-3.376-0.059-0.074-0.137-0.08-0.0650.156-0.0860.158-1.558-0.022-1.22-0.578-0.503
Operating Expenses 50.1748.56644.19843.28841.33738.86931.9624.27127.35224.12624.86720.19715.64115.76910.83111.94810.91410.5045.2284.8264.7735.178
Operating Income -50.439-48.483-46.455-43.28-41.337-38.869-31.96-27.976-30.728-24.126-4.867-20.197-15.541-15.769-13.291-11.948-10.914-10.504-2.728-2.326-2.651-2.858
Operating Income Ratio -1,363.216-584.133-324.86-5,4100000-307.280-0.2430-155.4100-4.779-4.366-4.202-1.091-0.93-1.06-1.143
Total Other Income Expenses Net 5.1825.3693.8123.843.8323.0652.2424.4673.462-0.06-0.074-0.137-0.08-0.0650.156-0.0860.158-1.558-0.022-1.22-0.578-0.503
Income Before Tax -45.257-43.114-40.243-39.44-37.505-35.804-29.718-23.509-27.266-24.186-4.942-20.335-15.622-15.835-10.676-12.036-10.757-12.064-2.751-3.549-2.853-3.183
Income Before Tax Ratio -1,223.162-519.446-281.42-4,9300000-272.660-0.2470-156.2200-4.814-4.303-4.826-1.1-1.42-1.141-1.273
Income Tax Expense 0-0.2773.812-0.213.832-3.0650.002-4.467-3.4620.0011.998-0.038-0.0790.050.082-0.1560.001-0.1722.302-1.2170.0020.002
Net Income -45.257-43.114-40.243-39.44-37.505-32.739-29.72-19.042-23.804-24.187-6.94-20.297-15.622-15.885-10.676-12.036-10.757-11.892-2.751-3.549-2.853-3.183
Net Income Ratio -1,223.162-519.446-281.42-4,9300000-238.040-0.3470-156.2200-4.814-4.303-4.757-1.1-1.42-1.141-1.273
EPS -1.25-1.46-1.34-1.33-1.27-1.15-1.09-0.75-0.99-1.01-0.3-0.87-0.67-0.68-0.49-0.6-0.61-0.65-0.31-0.4-0.32-0.36
EPS Diluted -1.25-1.46-1.34-1.33-1.27-1.15-1.09-0.75-0.99-1.01-0.3-0.87-0.67-0.68-0.49-0.6-0.61-0.65-0.31-0.4-0.32-0.36
EBITDA -50.133-48.483-39.996-43.28-37.314-35.637-29.718-23.383-26.958-24.072-4.941-20.231-15.53-15.754-10.675-12.034-10.846-10.441-0.368-3.491-2.224-2.633
EBITDA Ratio -1,354.946-584.133-279.692-5,4100000-269.580-0.2470-155.300-4.814-4.338-4.176-0.147-1.396-0.89-1.053